首页> 外文期刊>Hematological oncology >Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma
【24h】

Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma

机译:血小板衍生生长因子-AB在多发性骨髓瘤中与其他血管生成细胞因子相关的肿瘤生长和血管生成中的作用

获取原文
获取原文并翻译 | 示例
       

摘要

Angiogenesis is a complex process essential for the growth, invasion, and metastasis of various malignant tumours, including multiple myeloma (MM). Various angiogenic cytokines have been implicated in the angiogenic process. Among them, platelet-derived growth factor-AB (PDGF-AB) has been reported to be a potent stimulator of angiogenesis in many solid tumours and haematological malignancies, including MM. The aim of the study was to investigate the relationship between PDGF-AB, microvascular density (MVD), and various angiogenic cytokines, such as basic fibroblast growth factor (b-FGF), angiogenin (ANG), and interleukin-6 (IL-6), in MM patients. Forty-seven MM patients before treatment, 22 of whom were in plateau phase, were studied. We determined the serum levels of the aforementioned cytokines and MVD in bone marrow biopsies before and after treatment. Mean serum values of PDGF-AB, b-FGF, ANG, and MVD were significantly higher in patients compared with controls and with increasing disease stage. Significant positive correlations were observed between serum PDGF-AB, ANG, and IL-6 levels and MVD. Furthermore, we found significant positive correlations between PDGF-AB and b-FGF, IL-6, ANG, and β2 microglobulin. We also found that patients with high MVD had statistically significantly higher serum levels of PDGF-AB when a median MVD value of 7.7 was used as the cutoff point. Furthermore, a significant difference was found in serum levels of PDGF-AB between pre- and post-treatment patients. Finally, survival time was significantly higher in the low MVD group versus the high MVD group (76 vs 51months). Our results showed that there is a strong positive correlation between PDGF-AB and the studied angiogenic cytokines and MVD. It seems that PDGF-AB plays a role in the complex network of cytokines inducing bone marrow neovascularization in patients with MM.
机译:血管生成是各种恶性肿瘤(包括多发性骨髓瘤(MM))的生长,侵袭和转移必不可少的复杂过程。在血管生成过程中已经涉及了多种血管生成细胞因子。其中,血小板源性生长因子-AB(PDGF-AB)被报道是许多实体瘤和血液系统恶性肿瘤(包括MM)中血管生成的有效刺激剂。该研究的目的是研究PDGF-AB,微血管密度(MVD)和各种血管生成细胞因子(例如碱性成纤维细胞生长因子(b-FGF),血管生成素(ANG)和白介素6(IL- 6),在MM患者中。研究治疗前的47位MM患者,其中22位处于高原期。我们确定了治疗前后的骨髓活检中上述细胞因子和MVD的血清水平。患者的PDGF-AB,b-FGF,ANG和MVD的平均血清值均显着高于对照组,且病程不断增加。血清PDGF-AB,ANG和IL-6水平与MVD之间存在显着正相关。此外,我们发现PDGF-AB与b-FGF,IL-6,ANG和β2微球蛋白之间存在显着的正相关。我们还发现,当中值MVD值为7.7时,MVD高的患者的PDGF-AB血清水平统计学上显着较高。此外,发现治疗前和治疗后患者的PDGF-AB血清水平存在显着差异。最后,低MVD组的生存时间明显高于高MVD组(76个月与51个月)。我们的结果表明,PDGF-AB与研究的血管生成细胞因子和MVD之间存在很强的正相关性。似乎PDGF-AB在复杂的细胞因子网络中诱导MM患者骨髓新血管形成中起作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号